NCT04588077View on ClinicalTrials.gov

Comparison Between 2-dose Versus 3-dose Regimens of Heplisav B in Cirrhosis

PHASE4RecruitingINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

September 14, 2020

Primary Completion Date

December 1, 2028

Study Completion Date

December 1, 2028

Conditions
Hepatitis BCirrhosis, LiverChronic Liver Disease
Interventions
BIOLOGICAL

Heplisav-B Injectable Product, 2-dose regimen

Investigators will randomly assign patients into a 2-dose regimen.

BIOLOGICAL

Heplisav-B Injectable Product, 3-dose regimen

Investigators will randomly assign patients into a 3-dose regimen.

Trial Locations (1)

21202

RECRUITING

Mercy Medical Center, Baltimore

Sponsors
All Listed Sponsors
lead

Mercy Medical Center

OTHER